Etanercept is a TNF receptor fusion protein, not a monoclonal antibody, and its biosimilar availability splits sharply by market: established across the EU and UK since 2016, still patent-blocked from the US until 2029.
Etanercept is a TNF receptor fusion protein, not a monoclonal antibody, and one of the few biologics where market access genuinely splits by geography. Biosimilar etanercept has been on formulary across the EU, UK, Gulf, Africa, Latin America and Southeast Asia since 2016, while US buyers remain locked to the originator, Enbrel, under patent until 2029. M Care Exports sources both originator and biosimilar etanercept from Indian manufacturing partners for regulatory affairs teams and tender desks in served export markets, quoted to the buyer's own registered label.
Etanercept exporter and bulk supplier from India.
Etanercept ships as a temperature-controlled biologic, typically prefilled syringes or autoinjector pens packed for continuous 2 to 8 degrees Celsius transport, with cold chain documentation (time and temperature logging) accompanying every consignment. Export documentation is prepared to match the destination regulator's dossier, including certificate of pharmaceutical product, batch release certificates and, where the buyer is sourcing a biosimilar, the reference product comparability data cited in the approved label. Because etanercept is a biologic rather than a small-molecule generic, M Care confirms current registration status for the specific brand and market before quoting, since biosimilar approval and tender eligibility vary by country even within the same served region. Packing, labelling language and outer carton markings are aligned to the importer's national requirements on request.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Tumor necrosis factor (TNF) inhibitor: TNF receptor (p75) Fc fusion protein, biologic DMARD, sourced and documented for export.
Etanercept is a soluble TNF receptor fusion protein (TNFR2 linked to human IgG1 Fc), structurally distinct from the monoclonal antibody TNF inhibitors, and it is administered by subcutaneous injection rather than intravenous infusion. Its biosimilar history is unusually uneven by geography: the European Medicines Agency approved the first subcutaneous anti-TNF biosimilar, Benepali, in January 2016, with further approvals since, so etanercept biosimilars are an established formulary choice across the EU, UK and markets that recognise EMA or MHRA dossiers. Originally approved by FDA in 1998 for rheumatoid arthritis, etanercept is indicated across several chronic inflammatory conditions including psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. Buyers assessing this molecule are choosing between an originator and a biosimilar supply route, and the correct choice depends on their own market's registration status, not on the US position.
Active ingredient
Etanercept. Tumor necrosis factor (TNF) inhibitor: TNF receptor (p75) Fc fusion protein, biologic DMARD.
Forms and strengths
25 mg; 50 mg.
Indications
Etanercept is a recombinant fusion protein linking the extracellular ligand-binding domain of the human TNF receptor (p75) to the Fc portion of human IgG1. It acts as a soluble decoy receptor that binds soluble and membrane-bound TNF-alpha, reducing inflammatory signalling in chronic immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. It is administered by subcutaneous injection and is available as both the originator brand and, in markets that recognise EMA or MHRA dossiers, as approved biosimilars.
Administration
Subcutaneous injection. Solution for injection (prefilled syringe or prefilled autoinjector pen) and powder for reconstitution.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
M Care Exports supplies etanercept to regulatory affairs departments, hospital procurement units and licensed importers across the UK, EU, Gulf and GCC states, Africa, Latin America, Southeast Asia and CIS markets, where biosimilar etanercept already has formulary standing alongside the originator. Buyers typically fall into two groups: tender desks sourcing on an INN basis for public hospital formularies, and specialty distributors handling named-patient or private-market biologic supply. Both groups need documentation that matches their own national regulator's dossier requirements, whether that dossier references an EMA-approved biosimilar, a UK MHRA authorisation, or a WHO-listed reliance pathway. M Care confirms the specific line, strength and registration status against each enquiry rather than presenting a fixed catalogue position.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on etanercept.
A reviewing pharmacist checks that etanercept is being quoted as a subcutaneous-only presentation (prefilled syringe, autoinjector or vial for reconstitution), since it has no approved intravenous or intramuscular route, unlike the monoclonal antibody TNF inhibitors. The distinction between originator Enbrel and a biosimilar line matters for interchangeability and substitution rules, which differ by national pharmacopoeia and are not automatic even where both are registered. Storage integrity is the primary quality risk: etanercept is a protein biologic sensitive to freezing and to temperature excursion, so batch documentation should include continuous cold chain records, not just a release certificate. Reviewers also confirm the reference product and biosimilar comparability data cited in the destination label, since a biosimilar approved by one stringent regulatory authority is not automatically interchangeable or registrable against another authority's dossier without its own local filing.
The documentation pack a regulator actually asks for.
Every etanercept consignment is quoted against the destination market's own approved label and registration status, since originator and biosimilar etanercept do not share a single global dossier. Documentation includes a certificate of pharmaceutical product, batch-specific certificate of analysis, and cold chain transport validation records covering the full transit. Where the buyer is sourcing a biosimilar line, M Care provides the manufacturer's comparability and biosimilarity data as filed with the reference regulator (EMA, UK MHRA or the relevant stringent authority) rather than asserting interchangeability independently. M Care Exports itself holds ISO 9001:2015 certification and a CDSCO export licence as a merchant-exporter; it sources etanercept from Indian manufacturing partners that hold their own WHO-GMP status where applicable, and M Care does not claim WHO-GMP or WHO-PQ certification in its own name. All strength, presentation and indication claims are checked against the approved reference label before quotation.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
What a buyer should know before this line enters a formulary.
We publish the awkward facts alongside the useful ones. A supplier who omits them is not saving you work, only deferring it.
Boxed warning: serious infections including reactivation of latent tuberculosis and invasive fungal infections
Boxed warning: malignancy risk, including lymphoma and other cancers reported in children and adolescents
Approved only for subcutaneous injection; no intravenous or intramuscular route
Biosimilar substitution and interchangeability governed by national rules, not automatic across markets
Biosimilar etanercept remains patent-blocked from the US market until 2029, so only originator Enbrel is currently available there; the US is not a market M Care serves
Requires continuous 2 to 8 degrees Celsius cold chain from origin to destination
Adjacent lines procurement desks order alongside etanercept.
Infliximab
Another allergy & immunology line ordered on the same formularies.
Levocetirizine
Another allergy & immunology line ordered on the same formularies.
Mycophenolate
Another allergy & immunology line ordered on the same formularies.
All allergy & immunology
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for etanercept.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Etanercept supply, the specific questions.
What is the structural difference between etanercept and monoclonal antibody TNF inhibitors?
Etanercept is a fusion protein combining the extracellular portion of the human TNF receptor with an IgG1 Fc fragment, acting as a decoy receptor. Monoclonal antibody TNF inhibitors bind TNF directly through an antigen-binding site. The distinction affects dosing, immunogenicity profile and, practically, that etanercept is approved only for subcutaneous injection, never intravenous infusion.
Is biosimilar etanercept registered in our market, or only the originator?
It depends on the destination regulator. The EMA approved the first subcutaneous anti-TNF biosimilar in January 2016, and etanercept biosimilars are now an established formulary option across the EU, UK and many markets that recognise EMA or MHRA dossiers. M Care confirms current registration status for the specific market at enquiry rather than assuming coverage.
Why does the United States still only have originator Enbrel available?
US courts have upheld Amgen's patent position on etanercept, and FDA-approved biosimilars from other manufacturers remain blocked from the US market until patent expiry in 2029. The US is not a market M Care serves, but the split is relevant context: it shows how unevenly biosimilar access for this molecule varies by jurisdiction.
What is the main safety warning regulatory affairs teams should review for etanercept?
Etanercept carries a boxed warning for serious infections, including reactivation of latent tuberculosis and invasive fungal infections, and for malignancy risk, including lymphoma and other cancers reported in children and adolescents. Buyers should review the current approved label for the destination market, since warning language and monitoring requirements can differ between regulators.
Does M Care hold WHO-GMP or WHO-PQ certification directly?
No. M Care Exports is a merchant-exporter, not a manufacturer, and holds ISO 9001:2015 certification and a CDSCO export licence in its own name. Etanercept is sourced from Indian manufacturing partners that hold WHO-GMP status where applicable, and buyers requiring WHO-GMP or WHO-PQ documentation should request it as manufacturer-level evidence for the specific line quoted.
What documentation accompanies an etanercept export shipment?
A certificate of pharmaceutical product, batch-specific certificate of analysis and cold chain transport validation records covering the full transit are standard. Where a biosimilar line is being supplied, M Care also provides the manufacturer's biosimilarity and comparability data as filed with the reference regulator, so the buyer's own dossier can cite it directly.
Can M Care supply etanercept under the originator brand name, such as Enbrel?
M Care can source branded originator etanercept as well as biosimilar and generic lines, quoted against the buyer's own registered label and destination market. The brand name is referenced so buyers searching by trade name can identify the correct molecule; actual availability of a specific brand and strength is confirmed at enquiry.
Is a biosimilar etanercept automatically substitutable for the originator without a separate filing?
No. Interchangeability and substitution rules for biosimilars are set nationally and are not automatic even where both originator and biosimilar are registered in the same market. Buyers should confirm their own regulator's substitution policy before assuming a biosimilar line can replace an existing originator listing on a tender or formulary.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-22.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.